ClinicalTrials.gg
CompletedNCT01863888TERI-DYNAMICUpdated Mar 13, 2015

Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis

A Phase 3 interventional study of teriflunomide HMR1726 and cholestyramine in Multiple Sclerosis, sponsored by Sanofi. Completed at 10 sites in 3 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-13.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing teriflunomide in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. teriflunomide · Multiple Sclerosis.

Enrollment
18th of 22
70 · median 138
Started
2013
with 2 others
Phase 3
10 of 22
none open now
Registered
13th of 22
by date
Lead sponsor
17 of 22
Sanofi

Among the 22 studies testing teriflunomide in Multiple Sclerosis, this one is the 18th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 3, and was the 13th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 22 studies testing teriflunomide in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About teriflunomide

teriflunomide: first FDA approval 2012 (AUBAGIO), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing teriflunomide in Multiple Sclerosis as a file.
02

Study summary

Primary Objective:

To measure the effect of Teriflunomide on lymphocytes subsets in patients with relapsing forms of multiple sclerosis as compared with baseline values and those of a reference population of untreated healthy subjects.

Secondary Objectives:

To assess if Teriflunomide treatment results in biased T cell clonal diversity. To assess the effect of Teriflunomide on the function of peripheral blood mononuclear cells (proliferation and cytokine production in situ).

To assess the circulating cytokines profile in the serum of Relapsing Multiple Sclerosis (RMS) patients during a 24-week treatment versus baseline and healthy controls.

To assess the reversibility of all parameter changes in patients who discontinue treatment after accelerated elimination procedure with cholestyramine or activated charcoal.

Read the detailed description

The duration of the study for patients is 32 weeks which includes 4 weeks for screening, 24 weeks for treatment and 4 weeks for follow-up. An extension of the study is proposed until Teriflunomide is commercially available in the country where patient lives.

The duration of the study for healthy volunteers is 25 weeks which includes only one week for screening.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients (male and female) with relapsing forms of multiple sclerosis meeting McDonald criteria for MS at the screening visit and having either one of the following treatment status:

  • Naïve to disease modifying (DM) treatment or no DM treatment for more than 2 years
  • Or currently (not more than 3 months interruption) on MS therapy with IFN β-1 or Glatiramer acetate and a period of at least 2 weeks without IFN β-1 or Glatiramer acetate before switching to teriflunomide.

Male and female patients, between 18 and 56 years of age, exclusive.

Healthy volunteers:

Male and female subjects, between 18 and 56 years of age, exclusive. Body weight between 50.0 and 95.0 kg, inclusive, if male; and between 40.0 and 85.0 kg, inclusive, if female, between 18.0 and 30.0 kg/m2, inclusive.

Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).

Normal vital signs after 10 minutes resting in supine position:

  • 95 mmHg \< systolic blood pressure (SBP) \<140 mmHg
  • 45 mmHg \< diastolic blood pressure (DBP) \<90 mmHg
  • 40 bpm \< heart rate (HR) \<100 bpm Normal standard 12-lead (ECG) after 10 minutes resting in supine position; 120 ms \< PR \<220 ms, QRS \<120 ms, ≤ 430 ms if male, ≤ 450 ms if female.

Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects; however liver function parameter(s) should not exceed the upper laboratory norm.

Exclusion criteria

Exclusion criteria:

Did not consent to testing (the specifics of process for the HIV testing should be done in accordance with local guidelines).

A relapse within 30 days prior to screening. cardiovascular, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the patient at risk by participating in the study.

Patients with a congenital or acquired severe immunodeficiency, a history of cancer (except for basal or squamous cell skin lesions which have been surgically excised, with no evidence of ), lymphoproliferative disease, or any patient who has received lymphoid irradiation.

Human immunodeficiency virus (HIV) positive patients. Known history of active tuberculosis not adequately treated or positive QuantiFERON TB Gold test.

Hypoproteinemia (eg, in case of severe liver disease or nephrotic syndrome) with serum albumin \<3.0 g/dL.

Moderate to severe impairment of renal function, as shown by serum creatinine >133 μmol/L (or >1.5 mg/dL).

Patients with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia.

Acute or chronic infection. Liver function impairment or persisting elevations >1.5ULN (confirmed by retest) of serum glutamic pyruvic transaminase/ (SGPT/ALT), serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST), or direct greater than 1.5-fold the .

Use of adrenocorticotrophic hormone (ACTH) or systemic for 2 weeks prior to screening.

Prior or concomitant use of cytokine therapy or intravenous immunoglobulins in the 3 months prior to screening.

Prior use of alemtuzumab or cladribine. Prior use (within 1 year) of fingolimod (Gylenia®). Prior use (within 2 years) of mitoxantrone, natalizumab (Tysabri®), or agents (i.e. azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate).

Prior treatment with teriflunomide, and prior or concomitant use of leflunomide (ARAVA®) or to any of the other ingredients or of the product.

Prior use of any investigational drug in the 6 months preceding screening. Pregnant or breast-feeding women. Women of not utilizing effective method and /or women of childbearing potential who are unwilling to or unable to be tested for pregnancy.

Known history of hypersensitivity to teriflunomide or leflunomide. Persisting elevations (confirmed by retest) of serum amylase or lipase greater than 2-fold the upper limit of normal.

Known history of chronic pancreatic disease or pancreatitis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    teriflunomide (HMR1726)

    Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered.

    Drug: teriflunomide HMR1726 · Drug: cholestyramine · Drug: charcoal

  • No intervention
    Reference population

    Untreated healthy subjects

Interventions

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:powder Route of administration: oral

  • Pharmaceutical form:granule Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change from baseline in Lymphocyte subset parameters as measured by flow cytometry

    Time frame: At 12 weeks and 24 weeks

Secondary outcomes

  1. Change from baseline in biased T cell clonal repertoire based T cell receptor (TCR) spectratyping

    Time frame: At 12 weeks and 24 weeks

  2. Change from baseline in serum cytokine as measured by multicytokine array tool

    Time frame: At 12 weeks and 24 weeks

  3. Change from baseline in Mitogen/TCR-specific T cell proliferation as measured by flow cytometry

    Time frame: At 12 weeks and 24 weeks

07

Study locations

10 sites
  • Investigational Site Number 056001
    Brussels, 1070, Belgium
  • Investigational Site Number 056002
    Overpelt, 3900, Belgium
  • Investigational Site Number 056003
    Sijsele-Damme, 8340, Belgium
  • Investigational Site Number 276-003
    Bad Mergentheim, 97980, Germany
  • Investigational Site Number 276-004
    Hannover, 30625, Germany
  • Investigational Site Number 276-005
    Marburg, 35043, Germany
  • Investigational Site Number 276-007
    Mönchengladbach, 41061, Germany
  • Investigational Site Number 276-001
    Münster, 48149, Germany
  • Investigational Site Number 276-002
    Ulm, 89073, Germany
  • Investigational Site Number 528001
    Sittard-Geleen, 6162BG, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2013
First posted
May 29, 2013
Start
Oct 2013
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Last update
Mar 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01863888
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 29, 2013
Start date
Oct 2013
Primary completion
Jan 2015
Completion
Jan 2015
Last update
Mar 13, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Teriflunomide · Cholestyramine Resin · Charcoal

Start the discussion